# Effects of Dexmedetomidine Treatment After Cerebral Ischemia/Reperfusion on Apoptosis and Oxidative Stress: A Rat Model

**Authors:** Mahir Kuyumcu, Eda Yıldızhan

PMC · DOI: 10.3390/life16020325 · 2026-02-13

## TL;DR

This study shows that dexmedetomidine reduces brain damage in rats after ischemia/reperfusion by lowering oxidative stress and apoptosis.

## Contribution

The study demonstrates the neuroprotective effects of dexmedetomidine in a rat model of cerebral IR injury through oxidative stress and apoptotic modulation.

## Key findings

- Dex treatment improved antioxidant capacity and reduced oxidative stress markers in IR-injured rats.
- Dex attenuated neuronal damage and preserved ultrastructure following cerebral IR injury.
- Dex modulated Bax, Bcl-2, and APAF-1 expression toward control levels in IR-injured rats.

## Abstract

Objectives: Cerebral ischemia/reperfusion (IR) injury is characterized by excessive oxidative stress and activation of apoptotic pathways, which play a central role in neuronal loss and poor neurological outcomes. Modulation of these mechanisms represents a clinically relevant strategy for neuroprotection. This study aimed to investigate the neuroprotective effects of dexmedetomidine (Dex) on oxidative stress, apoptotic signaling, and neuronal integrity in an experimental rat model of cerebral IR injury. Materials and Methods: Female Wistar rats were assigned to control, IR, and IR+Dex groups. Transient cerebral ischemia was induced for 45 min followed by 2 h of reperfusion. Oxidative stress was evaluated using serum antioxidant enzyme activities (superoxide dismutase [SOD], catalase [CAT], glutathione peroxidase [GSH-Px]), total oxidant and antioxidant status (TOS, TAS), and lipid peroxidation levels (malondialdehyde [MDA]). Apoptotic signaling was assessed by histopathological examination, transmission electron microscopy, and immunohistochemical analysis of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and apoptotic peptidase activating factor-1 (APAF-1) expression, quantitatively evaluated using QuPath with statistical comparison between groups. Bioinformatic network analysis and molecular docking were performed to explore predicted interactions between Dex and apoptosis-related proteins. Results: Cerebral IR induced a marked oxidative imbalance, characterized by reduced antioxidant enzyme activities and increased lipid peroxidation. Dex treatment partially improved antioxidant capacity and reduced oxidative stress parameters. Histopathological and ultrastructural analyses demonstrated severe neuronal degeneration following IR, whereas Dex-treated rats exhibited attenuated neuronal damage and improved ultrastructural preservation. Immunohistochemical analysis showed increased Bax and APAF-1 expression and reduced Bcl-2 expression after IR; these alterations were significantly modulated toward control levels in the IR+Dex group. Bioinformatic analysis identified apoptosis-related pathways, including apoptosis, p53 signaling, and necroptosis, as significantly enriched, while molecular docking suggested stable predicted interactions between Dex and key apoptotic regulators. Conclusions: In this experimental rat cerebral IR model, Dex exerted partial but significant neuroprotective effects by attenuating oxidative stress, modulating apoptotic marker expression, and preserving neuronal morphology. These findings support the potential role of Dex as a neuroprotective agent in ischemia-related brain injury, warranting further translational investigation.

## Linked entities

- **Genes:** BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], APAF1 (apoptotic peptidase activating factor 1) [NCBI Gene 317], TP53 (tumor protein p53) [NCBI Gene 7157]
- **Chemicals:** Dexmedetomidine (PubChem CID 5311068), malondialdehyde (PubChem CID 10964)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CYBB (cytochrome b-245 beta chain) [NCBI Gene 1536] {aka AMCBX2, CGD, CGDX, GP91-1, GP91-PHOX, GP91PHOX}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, APAF1 (apoptotic peptidase activating factor 1) [NCBI Gene 317] {aka APAF-1, CED4}, XIAP (X-linked inhibitor of apoptosis) [NCBI Gene 331] {aka API3, BIRC4, IAP-3, ILP1, MIHA, XLP2}, CASP7 (caspase 7) [NCBI Gene 840] {aka CASP-7, CMH-1, ICE-LAP3, LICE2, MCH3}, Cat (catalase) [NCBI Gene 24248] {aka CS1, Cas1, Cat01, Catl, Cs-1}, p53-ps (Wistar clone pR53P1 p53 pseudogene) [NCBI Gene 301300], CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, FADD (Fas associated via death domain) [NCBI Gene 8772] {aka GIG3, IMD90, MORT1}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, Casp9 (caspase 9) [NCBI Gene 58918] {aka Apaf3, Casp-9-CTD, Casp9_v1, Ice-Lap6, Mch6}, TNFRSF10B (TNF receptor superfamily member 10b) [NCBI Gene 8795] {aka CD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, Bax (BCL2 associated X, apoptosis regulator) [NCBI Gene 24887], TNFRSF10A (TNF receptor superfamily member 10a) [NCBI Gene 8797] {aka APO2, CD261, DR4, TRAILR-1, TRAILR1}, Apaf1 (apoptotic peptidase activating factor 1) [NCBI Gene 78963], TXN (thioredoxin) [NCBI Gene 7295] {aka TRDX, TRX, TRX1, TXN1, Trx80}, CASP8 (caspase 8) [NCBI Gene 841] {aka ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Gpx1 (glutathione peroxidase 1) [NCBI Gene 24404] {aka GSHPx, GSHPx-1}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, Casp8 (caspase 8) [NCBI Gene 64044] {aka CASP-8}, CAT [NCBI Gene 100541757], PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Ripk1 (receptor interacting serine/threonine kinase 1) [NCBI Gene 306886], Mlkl (mixed lineage kinase domain like pseudokinase) [NCBI Gene 690743], Ripk3 (receptor-interacting serine-threonine kinase 3) [NCBI Gene 246240] {aka Hcyp2, Rip3}, Casp3 (caspase 3) [NCBI Gene 25402] {aka CPP32-beta, Lice, Yama}, Bcl2 (BCL2, apoptosis regulator) [NCBI Gene 24224] {aka Bcl-2}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}
- **Diseases:** inflammatory (MESH:D007249), injury (MESH:D014947), mitochondrial dysfunction (MESH:D028361), ischemic brain (MESH:D020520), Cerebral IR (MESH:D002545), neuroinflammation (MESH:D000090862), edema (MESH:D004487), acute stroke (MESH:D020521), ischemia (MESH:D007511), hypoxia (MESH:D000860), vacuolar degeneration (MESH:C536522), Cerebral ischemia/reperfusion (IR) injury (MESH:D015427), hypothermia (MESH:D007035), MCAO (MESH:D020244), brain injury (MESH:D001930), dehydration (MESH:D003681), infarct (MESH:D007238), Neuronal Degeneration (MESH:D009410), necrosis (MESH:D009336)
- **Chemicals:** paraffin (MESH:D010232), osmium tetroxide (MESH:D009993), phosphate (MESH:D010710), MDA (MESH:D015104), xylazine hydrochloride (MESH:D014991), xylene (MESH:D014992), water (MESH:D014867), nucleotide (MESH:D009711), copper (MESH:D003300), progesterone (MESH:D011374), ethanol (MESH:D000431), H&amp;E (MESH:D006371), hydrogen peroxide (MESH:D006861), Ca2+ (-), Hematoxylin (MESH:D006416), Na+ (MESH:D012964), K+ (MESH:D011188), Dex (MESH:D020927), MDA (MESH:D008315), epoxy resin (MESH:D004853), uranyl acetate (MESH:C005460), ketamine hydrochloride (MESH:D007649), citrate (MESH:D019343), propylene oxide (MESH:C009068), lipid (MESH:D008055), hydrogen (MESH:D006859), alcohol (MESH:D000438), Eosin (MESH:D004801), glutaraldehyde (MESH:D005976), 3,3'-diaminobenzidine (MESH:D015100), ROS (MESH:D017382), calcium (MESH:D002118), formalin (MESH:D005557)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941598/full.md

---
Source: https://tomesphere.com/paper/PMC12941598